Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers

Yohei Funatsu, Naoki Hasegawa, Hiroshi Fujiwara, Ho Namkoong, Takahiro Asami, Sadatomo Tasaka, Yoshifumi Kimizuka, Hirofumi Kamata, Makoto Ishii, Osamu Iketani, Haruhiko Ogata, Satoshi Iwata, Tomoko Betsuyaku

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Arbekacin is a unique aminoglycoside antibiotic with anti-methicillin-resistant Staphylococcus aureus activity. The efficacy of aminoglycosides is related to their serum maximum concentration. Local concentration of antibiotics in pulmonary epithelial lining fluid, rather than its serum concentration, can help determine its clinical efficacy more precisely for treatment of respiratory infectious disease. The objective of this study was to sequentially measure arbekacin concentration in epithelial lining fluid after infusion of a single clinically available dose.

Method: After the initial blood sampling, arbekacin was intravenously infused into 6 healthy volunteers over 1 h. Epithelial lining fluid and serum samples were collected by bronchoscopic microsampling 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after the start of 200 mg arbekacin infusion.

Results: Each probe sampled 10.1 ± 5.2 μl bronchial epithelial lining fluid. The sample dilution factor was 266.7 ± 157.1. Drug concentration was successfully measured in all but 2 of the epithelial lining fluid samples. The maximum concentration of arbekacin in epithelial lining fluid and serum was 10.4 ± 1.9 μg/ ml and 26.0 ± 12.2 μg/ml, respectively. The ratio of the maximum drug concentration in the epithelial lining fluid to that in the serum was 0.47 ± 0.19.

Conclusions: The maximum concentration of epithelial lining fluid reached levels that would effectively treat most clinical strains of methicillin-resistant S. aureus.

Original languageEnglish
Pages (from-to)607-611
Number of pages5
JournalJournal of Infection and Chemotherapy
Volume20
Issue number10
DOIs
Publication statusPublished - 2014 Oct 1

Fingerprint

Healthy Volunteers
Pharmacokinetics
Serum
Aminoglycosides
Methicillin-Resistant Staphylococcus aureus
Anti-Bacterial Agents
Pharmaceutical Preparations
Communicable Diseases
habekacin
Lung
Therapeutics

Keywords

  • Aminoglycoside
  • Arbekacin
  • Bronchoscopic microsampling
  • Epithelial lining fluid
  • Methicillin-resistant Staphylococcus aureus
  • Pharmacokinetic/pharmacodynamic

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers. / Funatsu, Yohei; Hasegawa, Naoki; Fujiwara, Hiroshi; Namkoong, Ho; Asami, Takahiro; Tasaka, Sadatomo; Kimizuka, Yoshifumi; Kamata, Hirofumi; Ishii, Makoto; Iketani, Osamu; Ogata, Haruhiko; Iwata, Satoshi; Betsuyaku, Tomoko.

In: Journal of Infection and Chemotherapy, Vol. 20, No. 10, 01.10.2014, p. 607-611.

Research output: Contribution to journalArticle

Funatsu, Y, Hasegawa, N, Fujiwara, H, Namkoong, H, Asami, T, Tasaka, S, Kimizuka, Y, Kamata, H, Ishii, M, Iketani, O, Ogata, H, Iwata, S & Betsuyaku, T 2014, 'Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers', Journal of Infection and Chemotherapy, vol. 20, no. 10, pp. 607-611. https://doi.org/10.1016/j.jiac.2014.05.007
Funatsu, Yohei ; Hasegawa, Naoki ; Fujiwara, Hiroshi ; Namkoong, Ho ; Asami, Takahiro ; Tasaka, Sadatomo ; Kimizuka, Yoshifumi ; Kamata, Hirofumi ; Ishii, Makoto ; Iketani, Osamu ; Ogata, Haruhiko ; Iwata, Satoshi ; Betsuyaku, Tomoko. / Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers. In: Journal of Infection and Chemotherapy. 2014 ; Vol. 20, No. 10. pp. 607-611.
@article{00d8a63621bc485098839eb8e9d2eead,
title = "Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers",
abstract = "Arbekacin is a unique aminoglycoside antibiotic with anti-methicillin-resistant Staphylococcus aureus activity. The efficacy of aminoglycosides is related to their serum maximum concentration. Local concentration of antibiotics in pulmonary epithelial lining fluid, rather than its serum concentration, can help determine its clinical efficacy more precisely for treatment of respiratory infectious disease. The objective of this study was to sequentially measure arbekacin concentration in epithelial lining fluid after infusion of a single clinically available dose.Method: After the initial blood sampling, arbekacin was intravenously infused into 6 healthy volunteers over 1 h. Epithelial lining fluid and serum samples were collected by bronchoscopic microsampling 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after the start of 200 mg arbekacin infusion.Results: Each probe sampled 10.1 ± 5.2 μl bronchial epithelial lining fluid. The sample dilution factor was 266.7 ± 157.1. Drug concentration was successfully measured in all but 2 of the epithelial lining fluid samples. The maximum concentration of arbekacin in epithelial lining fluid and serum was 10.4 ± 1.9 μg/ ml and 26.0 ± 12.2 μg/ml, respectively. The ratio of the maximum drug concentration in the epithelial lining fluid to that in the serum was 0.47 ± 0.19.Conclusions: The maximum concentration of epithelial lining fluid reached levels that would effectively treat most clinical strains of methicillin-resistant S. aureus.",
keywords = "Aminoglycoside, Arbekacin, Bronchoscopic microsampling, Epithelial lining fluid, Methicillin-resistant Staphylococcus aureus, Pharmacokinetic/pharmacodynamic",
author = "Yohei Funatsu and Naoki Hasegawa and Hiroshi Fujiwara and Ho Namkoong and Takahiro Asami and Sadatomo Tasaka and Yoshifumi Kimizuka and Hirofumi Kamata and Makoto Ishii and Osamu Iketani and Haruhiko Ogata and Satoshi Iwata and Tomoko Betsuyaku",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.jiac.2014.05.007",
language = "English",
volume = "20",
pages = "607--611",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers

AU - Funatsu, Yohei

AU - Hasegawa, Naoki

AU - Fujiwara, Hiroshi

AU - Namkoong, Ho

AU - Asami, Takahiro

AU - Tasaka, Sadatomo

AU - Kimizuka, Yoshifumi

AU - Kamata, Hirofumi

AU - Ishii, Makoto

AU - Iketani, Osamu

AU - Ogata, Haruhiko

AU - Iwata, Satoshi

AU - Betsuyaku, Tomoko

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Arbekacin is a unique aminoglycoside antibiotic with anti-methicillin-resistant Staphylococcus aureus activity. The efficacy of aminoglycosides is related to their serum maximum concentration. Local concentration of antibiotics in pulmonary epithelial lining fluid, rather than its serum concentration, can help determine its clinical efficacy more precisely for treatment of respiratory infectious disease. The objective of this study was to sequentially measure arbekacin concentration in epithelial lining fluid after infusion of a single clinically available dose.Method: After the initial blood sampling, arbekacin was intravenously infused into 6 healthy volunteers over 1 h. Epithelial lining fluid and serum samples were collected by bronchoscopic microsampling 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after the start of 200 mg arbekacin infusion.Results: Each probe sampled 10.1 ± 5.2 μl bronchial epithelial lining fluid. The sample dilution factor was 266.7 ± 157.1. Drug concentration was successfully measured in all but 2 of the epithelial lining fluid samples. The maximum concentration of arbekacin in epithelial lining fluid and serum was 10.4 ± 1.9 μg/ ml and 26.0 ± 12.2 μg/ml, respectively. The ratio of the maximum drug concentration in the epithelial lining fluid to that in the serum was 0.47 ± 0.19.Conclusions: The maximum concentration of epithelial lining fluid reached levels that would effectively treat most clinical strains of methicillin-resistant S. aureus.

AB - Arbekacin is a unique aminoglycoside antibiotic with anti-methicillin-resistant Staphylococcus aureus activity. The efficacy of aminoglycosides is related to their serum maximum concentration. Local concentration of antibiotics in pulmonary epithelial lining fluid, rather than its serum concentration, can help determine its clinical efficacy more precisely for treatment of respiratory infectious disease. The objective of this study was to sequentially measure arbekacin concentration in epithelial lining fluid after infusion of a single clinically available dose.Method: After the initial blood sampling, arbekacin was intravenously infused into 6 healthy volunteers over 1 h. Epithelial lining fluid and serum samples were collected by bronchoscopic microsampling 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after the start of 200 mg arbekacin infusion.Results: Each probe sampled 10.1 ± 5.2 μl bronchial epithelial lining fluid. The sample dilution factor was 266.7 ± 157.1. Drug concentration was successfully measured in all but 2 of the epithelial lining fluid samples. The maximum concentration of arbekacin in epithelial lining fluid and serum was 10.4 ± 1.9 μg/ ml and 26.0 ± 12.2 μg/ml, respectively. The ratio of the maximum drug concentration in the epithelial lining fluid to that in the serum was 0.47 ± 0.19.Conclusions: The maximum concentration of epithelial lining fluid reached levels that would effectively treat most clinical strains of methicillin-resistant S. aureus.

KW - Aminoglycoside

KW - Arbekacin

KW - Bronchoscopic microsampling

KW - Epithelial lining fluid

KW - Methicillin-resistant Staphylococcus aureus

KW - Pharmacokinetic/pharmacodynamic

UR - http://www.scopus.com/inward/record.url?scp=84908073737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908073737&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2014.05.007

DO - 10.1016/j.jiac.2014.05.007

M3 - Article

VL - 20

SP - 607

EP - 611

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 10

ER -